Rigel Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Rigel Pharmaceuticals Inc.
Fidelity Growth Company Fund
11,558,665
6.95%
-62,717
0.08%
07/31/2018
SPDR S&P Biotech ETF
5,618,954
3.38%
14,457
0.33%
09/06/2018
Oppenheimer Global Opportunities Fund
5,000,000
3%
0
0.18%
03/31/2018
Vanguard Total Stock Market Index Fund
4,097,563
2.46%
0
0%
07/31/2018
Wellington Mgmt. Port (Dublin) Plc - Global Health Care Eq.
3,979,820
2.39%
633,820
0.63%
12/31/2017
iShares Russell 2000 ETF
3,453,344
2.08%
-1,845
0.02%
09/06/2018
Fidelity Series Growth Company Fund
3,366,112
2.02%
0
0.09%
07/31/2018
T Rowe Price Small Cap Value Fund
2,956,700
1.78%
681,800
0.09%
06/30/2018
Vanguard Extended Market Index Fund
2,161,033
1.3%
0
0.01%
07/31/2018
Rhenman & Partners Fund - Healthcare Equity L/S
1,932,831
1.15%
556,931
0.47%
12/31/2017
| Address |
1180 Veterans Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.rigel.com |
| Updated |
07/08/2019 |
| Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. It focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. |
